NCT02996890View on ClinicalTrials.gov

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

January 4, 2018

Study Completion Date

April 17, 2018

Conditions
Zika Virus
Interventions
BIOLOGICAL

MV-ZIKA

MV-Zika vaccine

OTHER

Placebo

physiological saline

Trial Locations (2)

1090

Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Vienna

Medical University of Vienna, Department of Clinical Pharmacology, Vienna

All Listed Sponsors
lead

Themis Bioscience GmbH

INDUSTRY

NCT02996890 - Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) | Biotech Hunter | Biotech Hunter